Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BYSINASDAQ:CNTBNASDAQ:LRMRNASDAQ:RPHMNASDAQ:VCNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.91+6.1%$2.33$0.65▼$4.00$74.34M0.15191,015 shs80,207 shsCNTBConnect Biopharma$1.54+1.3%$1.44$0.53▼$2.84$84.81M-0.61149,120 shs32,224 shsLRMRLarimar Therapeutics$6.53+2.4%$9.21$2.18▼$13.68$416.61M0.93570,189 shs509,168 shsRPHMReneo Pharmaceuticals$1.74-1.1%$1.66$0.98▼$11.30$58.15M0.24280,559 shs82,987 shsVCNXVaccinex$4.86+1.3%$8.02$4.43▼$100.80$5.98M0.7411,803 shs7,888 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring-2.70%-12.62%-40.20%+104.55%+66.67%CNTBConnect Biopharma-1.94%-20.83%+23.08%+40.74%+42.06%LRMRLarimar Therapeutics-9.50%-11.63%-25.73%+49.07%+29.67%RPHMReneo Pharmaceuticals-0.56%+3.53%+6.67%+9.32%-80.31%VCNXVaccinex-0.83%-29.41%-42.03%-37.66%-95.03%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpring0.0016 of 5 stars0.00.00.00.00.02.50.0CNTBConnect Biopharma2.9586 of 5 stars3.53.00.00.03.72.50.6LRMRLarimar Therapeutics2.8517 of 5 stars4.51.00.00.02.73.30.0RPHMReneo Pharmaceuticals0.8677 of 5 stars2.90.00.00.00.62.51.3VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpringN/AN/A$1.25-34.55% DownsideCNTBConnect Biopharma3.00Buy$6.50322.08% UpsideLRMRLarimar Therapeutics3.00Buy$18.50183.31% UpsideRPHMReneo Pharmaceuticals1.88Reduce$18.14942.39% UpsideVCNXVaccinexN/AN/AN/AN/ACurrent Analyst RatingsLatest VCNX, RPHM, LRMR, BYSI, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.004/3/2024LRMRLarimar TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/3/2024LRMRLarimar TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.003/15/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$25.003/4/2024CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.002/20/2024LRMRLarimar TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/13/2024LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $10.002/13/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$17.00 ➝ $25.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.35M55.06N/AN/A($0.36) per share-5.31CNTBConnect BiopharmaN/AN/AN/AN/A$2.86 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/AVCNXVaccinex$570K10.49N/AN/A($2.59) per share-1.88Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/ACNTBConnect Biopharma-$114.44MN/A0.00N/AN/AN/AN/AN/AN/ALRMRLarimar Therapeutics-$36.95M-$0.85N/AN/AN/AN/A-38.83%-34.33%5/20/2024 (Estimated)RPHMReneo Pharmaceuticals-$77.39M-$2.52N/AN/AN/AN/A-73.14%-63.85%5/9/2024 (Estimated)VCNXVaccinex-$20.25M-$100.86N/A∞N/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)Latest VCNX, RPHM, LRMR, BYSI, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023LRMRLarimar Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/ALRMRLarimar TherapeuticsN/A9.499.49RPHMReneo PharmaceuticalsN/A5.875.87VCNXVaccinexN/A0.570.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%CNTBConnect Biopharma58.72%LRMRLarimar Therapeutics91.92%RPHMReneo Pharmaceuticals90.98%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%CNTBConnect Biopharma22.60%LRMRLarimar Therapeutics4.30%RPHMReneo Pharmaceuticals17.90%VCNXVaccinex51.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableCNTBConnect Biopharma10055.07 million42.63 millionOptionableLRMRLarimar Therapeutics4263.80 million61.06 millionOptionableRPHMReneo Pharmaceuticals5533.42 million27.44 millionOptionableVCNXVaccinex381.23 million598,000OptionableVCNX, RPHM, LRMR, BYSI, and CNTB HeadlinesSourceHeadlineVaccinex faces Nasdaq compliance challengeinvesting.com - April 14 at 7:54 AMVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023investorplace.com - April 2 at 3:02 PMVaccinex Reports 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 2 at 8:30 AMVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 27 at 8:30 AMVaccinex CFO Scott Royer to retire, Jill Sanchez steps ininvesting.com - March 6 at 7:15 PMVaccinex Inc VCNXmorningstar.com - March 2 at 3:46 PMVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technologyfinanznachrichten.de - February 21 at 9:42 AMVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platformmarkets.businessinsider.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyfinance.yahoo.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyglobenewswire.com - February 21 at 8:00 AMVaccinex Announces 1-For-14 Reverse Stock Splitmarkets.businessinsider.com - February 15 at 4:28 PMWhy Vaccinex (VCNX) Stock Is Trading Lowermsn.com - February 15 at 4:28 PMVaccinex, Inc. Announces Reverse Stock Splitglobenewswire.com - February 15 at 8:00 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Incfinance.yahoo.com - February 12 at 2:49 PMVaccinex Inc Secures $3.7M in Private Placement Dealmsn.com - February 8 at 10:26 AMWhy Vaccinex (VCNX) Stock Is Popping Offmsn.com - February 7 at 2:45 PMVaccinex Announces Pricing of $3.7 Million PIPE Financingmarkets.businessinsider.com - February 7 at 9:45 AMA phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.ascopubs.org - January 30 at 7:55 PMNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rulefinance.yahoo.com - December 4 at 8:50 AMVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:59 AMVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meetingfinance.yahoo.com - October 31 at 11:18 AMVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseasesfinance.yahoo.com - October 26 at 9:40 AMUnderstanding the Risks of Investing in Vaccinex Inc (VCNX)knoxdaily.com - October 17 at 9:03 PMVaccinex Inc [NASDAQ: VCNX] Sees Decrease in Stock Valueknoxdaily.com - October 6 at 7:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Connect BiopharmaNASDAQ:CNTBConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.Larimar TherapeuticsNASDAQ:LRMRLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Reneo PharmaceuticalsNASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.